Main Street Research LLC bought a new position in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) during the second quarter, Holdings Channel reports. The firm bought 2,500 shares of the biopharmaceutical company’s stock, valued at approximately $304,000.
A number of other institutional investors have also modified their holdings of ALXN. Guardian Life Insurance Co. of America raised its position in shares of Alexion Pharmaceuticals by 0.7% in the first quarter. Guardian Life Insurance Co. of America now owns 865 shares of the biopharmaceutical company’s stock worth $105,000 after buying an additional 6 shares during the period. Meeder Asset Management Inc. acquired a new position in shares of Alexion Pharmaceuticals during the first quarter worth $111,000. Independent Portfolio Consultants Inc. raised its position in shares of Alexion Pharmaceuticals by 46.9% in the first quarter. Independent Portfolio Consultants Inc. now owns 1,065 shares of the biopharmaceutical company’s stock worth $129,000 after buying an additional 340 shares during the period. FUKOKU MUTUAL LIFE INSURANCE Co raised its position in shares of Alexion Pharmaceuticals by 10.0% in the first quarter. FUKOKU MUTUAL LIFE INSURANCE Co now owns 1,100 shares of the biopharmaceutical company’s stock worth $133,000 after buying an additional 100 shares during the period. Finally, Princeton Alpha Management LP acquired a new position in shares of Alexion Pharmaceuticals during the first quarter worth $219,000. 94.75% of the stock is owned by institutional investors and hedge funds.
Alexion Pharmaceuticals, Inc. (NASDAQ ALXN) traded up 0.97% on Tuesday, reaching $127.00. The company had a trading volume of 675,690 shares. Alexion Pharmaceuticals, Inc. has a 1-year low of $96.18 and a 1-year high of $145.41. The stock has a market capitalization of $28.52 billion, a P/E ratio of 60.51 and a beta of 1.38. The stock’s 50 day moving average is $112.16 and its 200-day moving average is $122.31.
Alexion Pharmaceuticals (NASDAQ:ALXN) last issued its quarterly earnings data on Thursday, April 27th. The biopharmaceutical company reported $1.38 EPS for the quarter, beating the consensus estimate of $1.05 by $0.33. The company had revenue of $870 million for the quarter, compared to analyst estimates of $826.63 million. Alexion Pharmaceuticals had a return on equity of 11.72% and a net margin of 14.52%. Alexion Pharmaceuticals’s quarterly revenue was up 24.3% compared to the same quarter last year. During the same period last year, the company earned $1.11 earnings per share. On average, equities analysts predict that Alexion Pharmaceuticals, Inc. will post $5.32 EPS for the current fiscal year.
COPYRIGHT VIOLATION WARNING: This piece of content was originally posted by StockNewsTimes and is the property of of StockNewsTimes. If you are accessing this piece of content on another site, it was illegally stolen and republished in violation of US & international copyright & trademark law. The legal version of this piece of content can be read at https://stocknewstimes.com/2017/07/18/main-street-research-llc-buys-shares-of-2500-alexion-pharmaceuticals-inc-nasdaqalxn.html.
ALXN has been the subject of a number of recent analyst reports. TheStreet raised Alexion Pharmaceuticals from a “c” rating to a “b-” rating in a research report on Friday. Leerink Swann reissued a “buy” rating on shares of Alexion Pharmaceuticals in a research report on Tuesday, May 23rd. Instinet reissued a “buy” rating and issued a $148.00 target price on shares of Alexion Pharmaceuticals in a research report on Thursday, March 30th. UBS AG initiated coverage on Alexion Pharmaceuticals in a research report on Wednesday, March 29th. They issued a “buy” rating and a $138.00 target price for the company. Finally, Stifel Nicolaus reissued a “buy” rating and issued a $157.00 target price on shares of Alexion Pharmaceuticals in a research report on Wednesday, May 24th. Eight analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and one has assigned a strong buy rating to the stock. Alexion Pharmaceuticals has an average rating of “Buy” and a consensus price target of $156.62.
In other news, CEO Ludwig Hantson purchased 10,000 shares of the stock in a transaction dated Wednesday, June 14th. The shares were purchased at an average cost of $116.72 per share, with a total value of $1,167,200.00. Following the completion of the purchase, the chief executive officer now directly owns 38,725 shares of the company’s stock, valued at approximately $4,519,982. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Director Bros. Advisors Lp Baker purchased 1,348,955 shares of the stock in a transaction dated Wednesday, June 14th. The stock was purchased at an average cost of $116.32 per share, for a total transaction of $156,910,445.60. The disclosure for this purchase can be found here. Insiders bought 2,019,734 shares of company stock worth $235,606,846 over the last ninety days. Corporate insiders own 4.35% of the company’s stock.
Alexion Pharmaceuticals Company Profile
Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).
Want to see what other hedge funds are holding ALXN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN).
Receive News & Ratings for Alexion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
